Clinical Trial

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

Survival analyses with CNM-Au8 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baseline…

2 years ago

Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program

FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy studies of azenosertib Monotherapy data to be presented…

2 years ago

PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial

After a Reduction in Surgical Site Infection (SSI) Rates During COVID, Rates are Now Increasing, Signaling a Return to Pre-COVID…

2 years ago

Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

—Proteomic Analysis of Patient Samples Further Confirms that CCL24 is Associated with Primary Sclerosing Cholangitis (PSC) Severity and Progression, Highlighting…

2 years ago

Emergex Announces MHRA Approval of MIA (IMP) Manufacturing and Import Authorisation License

ABINGDON, United Kingdom, June 18, 2024 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical-stage biotechnology company…

2 years ago

NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US

NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease…

2 years ago

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of…

2 years ago

Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges

$10 million funding round from U.S. and EU strategic investors, will accelerate growth and empower efficient cultivated meat, fish and…

2 years ago

Anju Showcases Advanced eClinical Suite at DIA Global Annual Meeting 2024

FORT LAUDERDALE, Fla., June 17, 2024 /PRNewswire/ -- Anju Software, a trailblazer in comprehensive data and information management solutions for…

2 years ago

Avinger Announces Closing of up to $24 Million Public Offering

$6 million upfront with up to an additional $18 million of aggregate gross proceeds upon the exercise in full of…

2 years ago